论文部分内容阅读
目的探讨免疫荧光标记的方法测定脑钠肽对心力衰竭诊断的临床应用价值。方法设心衰组97例及对照组50例,利用荧光免疫法测定血浆脑钠肽,并进行心功能分级及标准化心衰评分,对心衰组与对照组、心衰组治疗前后实验数据,进行统计学处理比较分析。结果心衰组血浆脑钠肽为(874.3±853.5)ng/L;非心衰组脑钠肽(20.4±8.7)ng/L,非心衰组明显低于心衰组(P<0.01)。心衰患者经过抗心衰治疗后,血浆脑钠肽浓度下降至(328.8±336.2)ng/L,P<0.01,具统计学意义。治疗后NYHA心功能分级及标准化心衰评分均显著降低,P<0.01,具统计学差异。结论快速床旁检测脑钠肽测定在心衰诊断、心衰严重程度判断、治疗效果及预后判断中具有较高的应用价值,值得推广。
Objective To investigate the value of immunofluorescence labeling in the determination of brain natriuretic peptide in the diagnosis of heart failure. Methods 97 cases of heart failure group and control group of 50 cases, the use of fluorescence immunoassay of plasma brain natriuretic peptide, and cardiac function classification and standardized heart failure score, heart failure group and control group, heart failure group before and after treatment data, Statistical analysis and comparative analysis. Results The level of plasma brain natriuretic peptide was (874.3 ± 853.5) ng / L in non-heart failure group and 20.4 ± 8.7 ng / L in non-heart failure group (P <0.01). After anti-heart failure treatment in patients with heart failure, the concentration of plasma brain natriuretic peptide decreased to (328.8 ± 336.2) ng / L, P <0.01, with statistical significance. After NYHA function classification and standardized heart failure scores were significantly reduced, P <0.01, with statistical differences. Conclusion The rapid determination of brain natriuretic peptide in the vicinity of the bedside is of great value in the diagnosis of heart failure, the judgment of the severity of heart failure, the therapeutic effect and the prognosis. It is worth to be popularized.